Accelerating the development of
innovative discoveries into
life-changing biological medicines

 
 

With GENE to GMP™ we can help you achieve faster time-to-market, lower manufacturing costs and can rescue your promising drug candidates.

In June 2017, JSR Life Sciences acquired Selexis as part of JSR’s commitment to offer industry partners best-in-class contract development manufacturing (CDMO) services. Selexis SA and KBI Biopharma, which was acquired by JSR in 2015, have joined forces to provide industry partners “GENE to GMP in 9 Months” – 
the most robust and fastest service offering for the biopharmaceutical industry.

The Selexis SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 100 partners worldwide, 100+ drug candidates in clinical development and three commercial products utilizing Selexis-generated cell lines, the Company empowers scientists and biopharmaceutical companies around the world to realize the full potential of their research.

100+ clinical programs
3 marketed products
154 patents
9 key technology launches
 
101 PD programs
101 manufacturing batches
12 INDs per year
200+ analytical service projects

With more than 250 global partners, KBI’s broad range of product development services, expertise in biophysical and biochemical characterization of proteins, and flexible business model makes KBI a CDMO of choice. KBI's contract development and manufacturing services are built on a strategic cornerstone of deep analytical capabilities. We are passionate in the belief that detailed protein characterization drives speed, benefiting clients at every stage of the development and manufacturing process.

Faster time to clinic means

faster time to market

BEST-IN-CLASS

COMING TOGETHER

KBI’s mAb and non-mAb process platforms provide titers of 2-10 g/L using
20 Selexis cell lines
 
KBI has performed GMP manufacturing with
10 Selexis cell lines
 

OUR TIMELINES FOR A TYPICAL MAB

TO BE UPDATED

 

Reach the Clinic Faster

 

With GENE to GMP, we are committed to our partners' satisfaction. By predictably getting cGMP material for your clinical study, we help you concentrate on the other critical components of your development program.

 

Reach the Clinic Faster

 

With GENE to GMP, we are committed to our partners' satisfaction. By predictably getting cGMP material for your clinical study, we help you concentrate on the other critical components of your development program.

© Copyright 2018 GENE to GMP. All rights reserved.

LEGAL | PRIVACY | COOKIES